Antibacterial Protein SSL200 Lyses Staphylococci to Treat Bovine Mastitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bovine mastitis caused by Staphylococcus aureus are ineffective due to insufficient treatment effectiveness and frequent occurrence of resistant bacteria, highlighting the need for a more effective antibacterial agent.
Innovation Solution
Development of an antibacterial protein SSL200 with specific lytic activity against Staphylococci, including Staphylococcus aureus, utilizing an amino acid sequence represented by SEQ ID NO: 1, and its incorporation into a composition for treating bovine mastitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat bovine mastitis caused by Staphylococcus aureus, then treatment effectiveness is initially achieved, but resistant bacteria frequently occur and treatment effectiveness decreases
Solution Approach 1:
The patent changes the fundamental parameter of the antibacterial agent from conventional antibiotics to antibacterial proteins (SSLipase and SSL200). These proteins have different mechanisms of action that bypass bacterial resistance to traditional antibiotics, thereby maintaining treatment effectiveness while avoiding the resistance problem.
Solution Approach 2:
The patent combines multiple antibacterial proteins (SSLipase and SSL200) into a composite treatment composition. This combination approach creates synergistic effects where the proteins work together to enhance treatment effectiveness and prevent resistance development through multiple simultaneous mechanisms of action.
2Adaptability or versatility
If broad-spectrum antibiotics are used to treat bovine mastitis, then various bacteria are targeted, but side effects increase and beneficial bacteria are harmed
Solution Approach 1:
The antibacterial proteins SSLipase and SSL200 exhibit local quality in their antibacterial activity, specifically targeting Staphylococcus aureus and related staphylococci while sparing beneficial bacteria. This selective toxicity is achieved through specific molecular recognition mechanisms that distinguish pathogenic from commensal bacteria, reducing side effects while maintaining effective treatment.
3Quantity of substance
If existing treatments are used for bovine mastitis, then some bacterial reduction is achieved, but treatment effectiveness is insufficient and economic losses continue
Solution Approach 1:
The antibacterial proteins SSLipase and SSL200 act preliminarily and rapidly to reduce bacterial loads before the infection can establish itself or spread. This early intervention capability, combined with the proteins' stability and persistence in the mammary gland, ensures reliable treatment outcomes and prevents economic losses associated with prolonged mastitis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibacterial protein SSL200 effectively lyse Staphylococci, including Staphylococcus aureus, reducing bacterial loads and alleviating bovine mastitis symptoms, while minimizing side effects by targeting only the pathogenic bacteria.
Implementation Method 1
the antibacterial protein SSL200 having lytic activity against Staphylococci, including Staphylococcus aureus
Data Source
Figure 1
AI summary
The present invention relates to an antibacterial protein SSL200 having a specific antibacterial activity against Staphylococci including Staphylococcus aureus. More specifically, the present invention relates to: an antibacterial protein SSL200 specific for Staphylococci including Staphylococcus aureus, the protein being characterized by having the ability to specifically lyse Staphylococci including Staphylococcus aureus and having an amino acid sequence represented by SEQ ID NO: 1; and a composition for treating infections caused by Staphylococci including Staphylococcus aureus, the composition comprising, as an active ingredient, the antibacterial protein SSL200 specific for Staphylococci including Staphylococcus aureus.